Protocol Ledger

NCT07644052 · Phase III · RECRUITING

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

Interventional Phase III clinical trial protocol NCT07644052 sponsored by PleoPharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-17 Enrollment: 420 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07644052
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)420 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07644052
Protocol FieldVerified Registry Value
NCT IdentifierNCT07644052
Consolidated Lead SponsorPleoPharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment420 participants (ESTIMATED)
Registered Start Date2026-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07644052
Hospital Research SiteLocationSite Profile
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->
ForCare Clinical ResearchTampa, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI